Nippon Shokubai Partners with Taiwan's Biotech Industry to Usher in a New Era of Global CDMO Collaboration

Nippon Shokubai Co., Ltd., a global leader in the chemical industry, is set to participate in the 2024 Taiwan Healthcare+ Expo, unveiling its ambitious plans to expand its global CDMO operations. The company aims to actively seek partnerships with Taiwan's biotech and pharmaceutical sectors, exploring new opportunities for growth and innovation.

The Rise of the Global CDMO Market: A Golden Opportunity for Biotech

The global CDMO market is experiencing rapid growth, with forecasts projecting its size to reach $143.7 billion by 2024 and surpass $247.9 billion by 2029, representing a compound annual growth rate of 11.52%. The Japanese CDMO market, meanwhile, is expected to reach $19.49 billion by 2030, underscoring its strong growth potential.

Taiwan, recognized as a hub for biotech innovation in the Asia-Pacific region, is emerging as a leader in new drug development, regenerative medicine, and supply chain integration. The passage of the Dual Acts for Regenerative Medicine has further solidified Taiwan's position as a preferred partner for international pharmaceutical and CDMO companies. Nippon Shokubai's entry into the Taiwanese market marks a significant step toward fostering global collaboration in the CDMO sector, unlocking new opportunities across the industry value chain.

Nippon Shokubai: A Pioneer in Technology and Global Expansion

Founded in 1941, Nippon Shokubai has evolved from a traditional chemical manufacturer into a diversified company with a strong foothold in the high-value biotech and pharmaceutical sectors. With manufacturing and R&D facilities in Japan, the United States, Belgium, Singapore, China, and Taiwan, the company has established an extensive global network spanning Europe, Asia, and North America.

The collaboration will focus on cutting-edge areas such as oligonucleotide drugs, peptide drugs, and drug delivery systems (DDS)—core technologies driving the future of the biotech industry. Leveraging its expertise in custom-tailored services and comprehensive support, Nippon Shokubai delivers efficient and reliable solutions across the entire drug development lifecycle, from early-stage research to large-scale commercialization.

As the world's largest producer of superabsorbent polymers, Nippon Shokubai's unparalleled technical expertise in the intersection of chemicals and pharmaceuticals continues to drive innovation. By offering flexible collaboration models and customized services, the company not only meets market demands but also leads transformative changes in the biotech and pharmaceutical industries.

CDMO: Redefining Biotech Industry Dynamics

Often referred to as the "TSMC of the biotech world," the CDMO is revolutionizing the global pharmaceutical landscape. By separating drug development from manufacturing, CDMOs help pharmaceutical companies reduce costs, accelerate time-to-market, and mitigate production risks. Nippon Shokubai is a key enabler of this model, providing end-to-end solutions that empower biotech and pharmaceutical companies worldwide.

For Taiwan’s biotech industry, partnering with Nippon Shokubai offers a gateway to integrating into the global supply chain and accessing advanced technologies and resources. Against the backdrop of rapid growth in the global biotech market, this deep collaboration has the potential to significantly enhance the international competitiveness of Taiwanese biotech enterprises.

Japan and Taiwan Join Forces to Navigate the Blue Ocean of Biotech

Nippon Shokubai's participation in the 2024 Taiwan Healthcare+ Expo highlights its commitment to the Asia-Pacific market and its vision for fostering deeper collaboration between Japan and Taiwan's biotech sectors. With its cutting-edge technology and expansive market network, Nippon Shokubai delivers high-efficiency solutions to the pharmaceutical industry while driving continuous innovation across the value chain.

For Taiwan's biotech companies, this collaboration represents more than just a multinational partnership—it is a starting point for redefining global competitiveness. The 2024 Taiwan Healthcare+ Expo will serve as a platform not only for showcasing groundbreaking technologies and business opportunities but also for shaping the future landscape of the biotech industry.

● Also Want to Explore More Business Opportunities?
【Register for the 2024 Heathcare+ Expo Now to find the best partners! ▸】